HIMS

Hims & Hers Health, Inc.
CAPPED RATING

Hims & Hers Health, Inc. is an American telehealth company that sells prescription and over-the-counter drugs online, as well as personal care products. The company is best known for selling generic treatments for erectile dysfunction and hair loss.

Hims & Hers Health, Inc. (HIMS) is rated C (2.4/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Growth (B-); its weakest is Revisions (D).

Quantitative Factor Evaluation • Updated

Overall Rating
2.4 / 5.0
C
Value
C+
Factor Score 2.6 / 5.0
Growth
B-
Factor Score 3.0 / 5.0
Profitability
C+
Factor Score 2.7 / 5.0
Momentum
C+
Factor Score 2.6 / 5.0
Revisions
D
Factor Score 1.3 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 48.8
EV / EBITDA -72.5
Rev Growth YoY 48.6%
Gross Margin 64.8%
Price Return 3M -31.0%
Price Return 12M -49.4%
Catalyst Signal -0.14
Market Cap $4.6B
TTM Revenue $2.9B
Price / Sales 1.6
ROE -40.8%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-16 C+ (2.6) B- (3.0) C+ (2.7) C+ (2.6) D (1.3) C (2.4)
2026-11-09 C+ (2.8) B+ (3.6) C+ (2.7) C (2.5) D (1.3) C+ (2.6)
2026-11-02 C+ (2.8) B+ (3.6) C+ (2.7) C+ (2.7) D (1.4) C+ (2.6)
2026-10-30 C+ (2.8) B+ (3.6) C+ (2.7) C (2.3) D (1.4) C+ (2.6)
2026-10-26 C+ (2.8) B+ (3.6) C+ (2.7) C (2.3) D (1.4) C+ (2.6)
Page 1 of 10
…